ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,227Medicare Part D Prescriptions Filled, Including Refills

Rank: 550 out of 1456

$508K Total Retail Price of All Prescriptions

Rank: 440 out of 1456

370 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
8% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Georgia
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 370 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

12% of this provider’s 370 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

3% of this provider’s 6,877 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

32% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$70 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Georgia
LEVOTHYROXINE SODIUM 349 335 1 4
SIMVASTATIN 310 284 2 2
AMLODIPINE BESYLATE 209 204 3 1
CRESTOR 196 196 4 26
HYDROCHLOROTHIAZIDE 188 181 5 10
LOSARTAN POTASSIUM 181 177 6 16
LISINOPRIL 168 149 7 3
ALENDRONATE SODIUM 150 150 8 36
ATORVASTATIN CALCIUM 135 132 9 11
HYDROCODONE-ACETAMINOPHEN 121 120 S3 10 6
LISINOPRIL-HYDROCHLOROTHIAZIDE 117 109 11 24
BISOPROLOL FUMARATE 111 107 12 208
ATENOLOL 97 91 13 18
TAMSULOSIN HCL 94 92 14 34
METFORMIN HCL ER 90 90 15 54
FENOFIBRATE 78 73 16 56
BISOPROLOL-HYDROCHLOROTHIAZIDE 74 74 17 93
METFORMIN HCL 73 71 18 8
LIPITOR 68 68 19 76
DONEPEZIL HCL 68 68 19 29
TRIAMTERENE-HCTZ 65 63 21 49
GUANFACINE HCL 64 64 R 22 294
FINASTERIDE 62 62 23 110
FUROSEMIDE 61 60 24 7
NIFEDIPINE ER 61 61 24 81
SYNTHROID 59 59 26 37
ZOLPIDEM TARTRATE 58 58 27 14
GABAPENTIN 57 56 28 13
LOSARTAN-HYDROCHLOROTHIAZIDE 56 56 29 41
SERTRALINE HCL 56 56 29 25
METOPROLOL SUCCINATE 56 56 29 19
LANTUS SOLOSTAR 55 55 32 120
TRAMADOL HCL 55 53 32 17
RANITIDINE HCL 55 49 32 27
CITALOPRAM HBR 54 50 35 22
BYSTOLIC 52 52 36 102
NEXIUM 52 51 36 23
OMEPRAZOLE 52 38 36 5
NAMENDA 52 52 36 38
ALLOPURINOL 52 47 36 31
TRICOR 51 51 41 92
VESICARE 51 51 41 200
TRAZODONE HCL 51 48 41 47
METOPROLOL TARTRATE 50 47 44 12
DOXAZOSIN MESYLATE 50 50 44 84
PRAVASTATIN SODIUM 50 50 44 9
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.